Others were more present in the control group, among them apoA-I, apoA-II, apoL-I, apoM, and paraoxonase 1 (PON-1), probably conferring greater damage to the antiatherogenic activities of HDL in CKD. This evidence concerns the gene APOM and chronic kidney disease.